Early Access

10-QPeriod: Q1 FY2018

CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2018

Filed May 2, 2018For Securities:CVS

Summary

CVS Health's first-quarter 2018 results, as reported in their May 1, 2018, 10-Q filing, indicate a company navigating through operational performance while looking ahead to significant strategic developments. The report details the financial performance for the period ending March 30, 2018, and provides insights into the company's financial condition. Investors should pay close attention to the details within the Management's Discussion and Analysis (MD&A) section, which will likely elaborate on the drivers of revenue and profitability, as well as any emerging risks or opportunities. While specific unaudited financial statement figures for the quarter are presented, the most critical context for investors at this time is the pending acquisition of Aetna. This transformative deal, announced in late 2017, is expected to reshape CVS Health's business model and market position. Investors will be scrutinizing how the company is managing its current operations in light of this significant pending transaction and what preliminary impacts, if any, are being observed or managed.

Financial Statements
Beta
Revenue$45.74B
Cost of Revenue$37.51B
Gross Profit$6.86B
Operating Expenses$43.75B
Operating Income$2.00B
Interest Expense$523.00M
Net Income$998.00M
EPS (Basic)$0.98
EPS (Diluted)$0.98
Shares Outstanding (Basic)1.02B
Shares Outstanding (Diluted)1.02B

Key Highlights

  • 1The 10-Q filing covers the first quarter of 2018, detailing the financial performance for the period ending March 30, 2018.
  • 2Key financial statements, including Consolidated Statements of Income, Comprehensive Income, Balance Sheets, and Cash Flows, are presented on an unaudited basis.
  • 3Management's Discussion and Analysis (MD&A) is a critical section for understanding the operational results and financial condition.
  • 4The filing includes disclosures related to Legal Proceedings, providing an update on any significant ongoing litigation.
  • 5Information on Unregistered Sales of Equity Securities and Use of Proceeds is also included, which can be relevant for shareholding structure and capital management.
  • 6The report is filed against the backdrop of the pending acquisition of Aetna, a major strategic event for CVS Health.
  • 7Investors should look for commentary in the MD&A regarding how the pending Aetna acquisition is being managed and its potential impacts.

Frequently Asked Questions